Next generation dengue vaccines: A review of candidates in preclinical development

Julia Schmitz; John Roehrig; Alan Barrett; Joachim Hombach

doi:10.1016/j.vaccine.2011.07.017

Next generation dengue vaccines: A review of candidates in preclinical development

Julia Schmitz, John Roehrig, Alan Barrett, Joachim Hombach

Pathology

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.

Original language	English (US)
Pages (from-to)	7276-7284
Number of pages	9
Journal	Vaccine
Volume	29
Issue number	42
DOIs	https://doi.org/10.1016/j.vaccine.2011.07.017
State	Published - Sep 23 2011

Keywords

Dengue
Dengue vaccines
Dengue virus

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2011.07.017

Cite this

@article{20d136d548da4777b1b387c25d0dec0f,

title = "Next generation dengue vaccines: A review of candidates in preclinical development",

abstract = "Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.",

keywords = "Dengue, Dengue vaccines, Dengue virus",

author = "Julia Schmitz and John Roehrig and Alan Barrett and Joachim Hombach",

note = "Funding Information: Participants of the WHO/IVI Informal Consultation on Next Generation Dengue Vaccines and Diagnostics (1–2 November 2010, Atlanta) are thanked for sharing unpublished data. Preclinical stage dengue vaccine candidates were presented at the consultation by Drs. Martin Bachmann (Cytos Biotechnology), Gwong-Jen Chang (CDC), John Dong (GenPhar), Bruce Innis (GSK), Niranjan Y. Sardesai (Inovio Pharmaceuticals) and David B. Weiner (University of Pennsylvania), Alan Shaw (VaxInnate), Sathyamangalam Swaminathan (ICGEB), Erich Tauber (Themis Bioscience) and Laura White (UNC). Financial support of the consultation from the Bill and Melinda Gates Foundation is kindly acknowledged.",

year = "2011",

month = sep,

day = "23",

doi = "10.1016/j.vaccine.2011.07.017",

language = "English (US)",

volume = "29",

pages = "7276--7284",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "42",

}

TY - JOUR

T1 - Next generation dengue vaccines

T2 - A review of candidates in preclinical development

AU - Schmitz, Julia

AU - Roehrig, John

AU - Barrett, Alan

AU - Hombach, Joachim

N1 - Funding Information: Participants of the WHO/IVI Informal Consultation on Next Generation Dengue Vaccines and Diagnostics (1–2 November 2010, Atlanta) are thanked for sharing unpublished data. Preclinical stage dengue vaccine candidates were presented at the consultation by Drs. Martin Bachmann (Cytos Biotechnology), Gwong-Jen Chang (CDC), John Dong (GenPhar), Bruce Innis (GSK), Niranjan Y. Sardesai (Inovio Pharmaceuticals) and David B. Weiner (University of Pennsylvania), Alan Shaw (VaxInnate), Sathyamangalam Swaminathan (ICGEB), Erich Tauber (Themis Bioscience) and Laura White (UNC). Financial support of the consultation from the Bill and Melinda Gates Foundation is kindly acknowledged.

PY - 2011/9/23

Y1 - 2011/9/23

N2 - Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.

AB - Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development.

KW - Dengue

KW - Dengue vaccines

KW - Dengue virus

UR - http://www.scopus.com/inward/record.url?scp=80052408375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052408375&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.017

DO - 10.1016/j.vaccine.2011.07.017

M3 - Article

C2 - 21781998

AN - SCOPUS:80052408375

SN - 0264-410X

VL - 29

SP - 7276

EP - 7284

JO - Vaccine

JF - Vaccine

IS - 42

ER -

Next generation dengue vaccines: A review of candidates in preclinical development

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this